<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271309</url>
  </required_header>
  <id_info>
    <org_study_id>05/2007_Ferrara</org_study_id>
    <nct_id>NCT01271309</nct_id>
  </id_info>
  <brief_title>Stem Cell Migratory Activity: Prognostic Marker in Myocardial Ischemia</brief_title>
  <official_title>Migratory and Angiogenic Dysfunction of Circulating CD133 Stem Cells: a New Prognostic Marker in Myocardial Ischemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Multimedica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Ferrara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Multimedica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present project aims to determine whether a deficit in migration of stem cells could be&#xD;
      implicated in the failure to mount an adequate collateralization after Myocardial Infarction&#xD;
      (MI) and thereby facilitate the development of post-ischemic heart failure (HF) and to&#xD;
      dissect underlying molecular mechanisms. Furthermore, the investigators wish to determine the&#xD;
      predictive value of stem cell migration assay in patients with MI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MAIN OBJECTIVES OF THE STUDY:&#xD;
&#xD;
      Characterization of circulating CD133+ stem cells in a group of 170 patients with MI (mean&#xD;
      post-MI follow up, 6 months):&#xD;
&#xD;
        -  Counting total mononuclear cells and FACS analysis of CD133 stem cells.&#xD;
&#xD;
        -  Characterization of CD133+ stem cell biology: Migratory assay, imaging of cytoskeleton,&#xD;
           angiogenesis tests in vitro.&#xD;
&#xD;
        -  Evaluation of migratory signalling, with specific focus on the PI3K/Akt/eNOS system.&#xD;
&#xD;
      Assessment of the prognostic value of the stem cell migration assay.&#xD;
&#xD;
        -  Relationship between cell biology tests on CD133+ cells and changes in circulating&#xD;
           cytokines and pro-angiogenic factors after MI.&#xD;
&#xD;
        -  Assessment of area at risk by ECG-synchronized Single Photon Emission Computed&#xD;
           Tomography (gated-SPECT) in subgroups with different patterns of stem cell migratory&#xD;
           tests.&#xD;
&#xD;
        -  Assessment of ventricular remodelling (echocardiography, NMR) in relation with patterns&#xD;
           of stem cell migratory test.&#xD;
&#xD;
      EXPECTED RESULTS:&#xD;
&#xD;
      Clarification of the implication of stem cell migratory deficit in post-ischemic HF.&#xD;
&#xD;
        -  Identification of underlying mechanisms&#xD;
&#xD;
        -  Identification of a cellular marker for prediction of patients at risk of HF.&#xD;
&#xD;
      RELEVANCE TO PUBLIC HEALTH:&#xD;
&#xD;
        -  Introduction of a biological test for the early diagnosis of post-MI HF&#xD;
&#xD;
        -  Recognition of therapeutic targets for the rescue of stem cell migratory liabilities&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prognostic value of CD133+ stem cells in MI</measure>
    <time_frame>12 months</time_frame>
    <description>Correlation of clinical parameters of disease evolution and biological features</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of disease evolution and other biomarkers</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">170</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Acute Myocardial Infarction patients</arm_group_label>
    <description>Patients with thoracic pain lasting at least 20 min and ST changes or left B block, not present in previous ECG.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited sequentially at the Operative Unit of Ferrara having the&#xD;
        following characteristics: Thoracic pain lasting at least 20 min and ST changes or left B&#xD;
        block, not present in previous ECG. MI will be confirmed by elevation of troponin I and&#xD;
        CK-MB. Patients will be treated according to international guidelines. With regard to&#xD;
        medical treatment, this will include all available drugs except for statins, which will be&#xD;
        inserted only 14 days post-MI, to avoid the confounding effect of these drugs on stem cell&#xD;
        biology.&#xD;
&#xD;
        Patients reporting thoracic pain 24 hours prior to hospitalization will be excluded.&#xD;
        Similarly, those with HF symptoms resistant to therapy will be excluded. By contrast,&#xD;
        patients with Killip II e III LV dysfunction will be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Thoracic pain lasting at least 20 min and ST changes or left B block, not present in&#xD;
             previous ECG.&#xD;
&#xD;
          -  MI confirmed by elevation of troponin I and CK-MB.&#xD;
&#xD;
          -  Patients with Killip II e III LV dysfunction will be included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients reporting thoracic pain 24 hours prior to hospitalization&#xD;
&#xD;
          -  HF symptoms resistant to therapy&#xD;
&#xD;
          -  Haemoglobin&lt; 10 gr/dl&#xD;
&#xD;
          -  Haemodynamic instability (systolic pressure &lt;90 mmHg after treatment)&#xD;
&#xD;
          -  Alterations in haematopoiesys&#xD;
&#xD;
          -  Concurrent neoplastic disease&#xD;
&#xD;
          -  No written informed consent or other conditions that affect patient's compliance to&#xD;
             protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Valgimigli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Ferrara Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology Dept. Arcispedale S.Anna</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Multimedica</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Fortunato O, Spinetti G, Specchia C, Cangiano E, Valgimigli M, Madeddu P. Migratory activity of circulating progenitor cells and serum SDF-1Î± predict adverse events in patients with myocardial infarction. Cardiovasc Res. 2013 Nov 1;100(2):192-200. doi: 10.1093/cvr/cvt153. Epub 2013 Jun 12.</citation>
    <PMID>23761401</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>January 5, 2011</study_first_submitted>
  <study_first_submitted_qc>January 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2011</study_first_posted>
  <last_update_submitted>August 7, 2013</last_update_submitted>
  <last_update_submitted_qc>August 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

